Full Press Release Details
and REPLACING - Microbot Medical Appoints Eyal Morag M.D. as Chief Medical Officer
Mass., March 03, 2020 (GLOBE NEWSWIRE) - In a release issued under the same headline earlier today by Microbot Medical Inc.
(NASDAQ: MBOT), please note that in the first paragraph the appointment of Eyal Morag, M.D. has been changed to commencing
June 2020 and in the fourth paragraph Dr. Morag still currently serves as Chairman of Radiology at Assuta Ashdod Medical Center,
Ashdod, Israel. The corrected release follows:
Medical Inc. (NASDAQ: MBOT), announced the appointment of Eyal Morag, M.D., a leading radiologist, to Chief Medical Officer, commencing
June 2020. In his new role, Dr. Morag will lead the development and execution of the clinical strategy of the Company's
technology platforms, including its current development of the Self-Cleaning Shunt (SCS) and LIBERTY products as well as its future
pipeline. Dr. Morag has been a member of the Company's Scientific Advisory Board since November 2017 and will report directly
to Harel Gadot, Chief Executive Officer, President, and Chairman.
"Dr. Morag is highly-regarded in
the radiology community, and has been a valued member of our Scientific Advisory Board, having played an integral part in the
creation of our LIBERTY device. I am pleased that he sees the potential in our endovascular solutions, and as such will be
joining us full-time to become part of our leadership team," commented Mr. Gadot. "I am confident his contributions
to date, combined with his expertise and experience, will allow us to achieve our near- and long-term development, regulatory,
and commercialization plans."
Morag is certified by the American Board of Radiology and currently serves as Chairman of Radiology at Assuta Ashdod Medical Center,
Ashdod, Israel. He is a graduate of Boston University School of Medicine and completed both his Radiology residency and Fellowship
in Cardiovascular & Interventional Radiology at the Beth Israel Deaconess Medical Center & Harvard Medical School. Following
his clinical training, Dr. Morag joined a private practice in western Massachusetts, where he served as Chief of Radiology at
Holyoke Medical Center for several years. He has also served as the Regional Radiology Director at Mercy Health Partners Hospitals
in Toledo, Ohio, and was a member of the University Radiology Group (one of the largest private Radiology groups in the U.S.)
where he headed the International Investment efforts for the Ventures division.
Morag's extensive international experience developing and establishing radiology-related businesses includes teleradiology,
interventional Radiology services, and free-standing imaging centers. During his fellowship, Dr. Morag co-founded InTek Technology,
a medical device startup company. Later he founded Global Versa Radiology (GVR), an Israeli and U.S. based Teleradiology Company
that has expanded reach to provide Interventional Radiology services to U.S. hospitals. GVR has established imaging centers in
Russia and Ukraine and provided teleradiology services in countries outside the U.S. and Israel. Dr. Morag has served as GVR's
Chief Medical Officer and Vice-President.
Microbot Medical Inc.
Medical Inc. (MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies,
focused primarily on both natural and artificial lumens within the human body. Microbot's current proprietary technology
platforms provide the foundation for the development of a Multi-Generation Pipeline Portfolio (MGPP).
Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein to improve clinical outcomes for patients
and increase accessibility through the use of micro-robotic technologies. Further information about Microbot Medical is available
pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential
opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs,
goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not
limited to statements that contain words such as "will," "believes," "plans," "anticipates,"
"expects" and "estimates") should also be considered to be forward-looking statements. Forward-looking
statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization
of potential products, the outcome of its studies to evaluate the SCS, LIBERTY and other existing and future technologies, uncertainty
in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, need and ability to obtain
future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated
in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the businesses
of Microbot Medical Inc. particularly those mentioned in the cautionary statements found in Microbot Medical Inc.'s filings
with the Securities and Exchange Commission. Microbot Medical disclaims any intent or obligation to update these forward-looking